TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Stock BOERSE MUENCHEN
Equities
TKDA
US8740602052
Pharmaceuticals
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.9 EUR | 0.00% |
|
-4.03% | -7.75% |
| Sales 2024 | 4,264B 26.91B 25.1B 36.87B | Sales 2025 * | 4,281B 27.02B 25.2B 37.02B | Capitalization | 6,312B 39.83B 37.15B 54.58B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 909M 848M 1.25B | Net income 2025 * | 92.57B 584M 545M 800M | EV / Sales 2024 | 2.57 x |
| Net Debt 2024 | 4,386B 27.68B 25.82B 37.93B | Net Debt 2025 * | 4,189B 26.43B 24.65B 36.22B | EV / Sales 2025 * | 2.45 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
69.4
x | Employees | - |
| Yield 2024 |
4.49% | Yield 2025 * |
4.84% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 week | -4.03% | ||
| Current month | -2.46% | ||
| 1 month | -2.46% | ||
| 3 months | -9.85% | ||
| 6 months | -5.56% | ||
| Current year | -7.75% |
1 week
11.80
12.40
1 month
11.8012.50
3 years
11.7015.60
5 years
11.7018.80
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 11.9 | 0.00% |
| 24-06-19 | 11.9 | +0.85% |
| 24-06-18 | 11.8 | -3.28% |
| 24-06-17 | 12.2 | 0.00% |
| 24-06-14 | 12.2 | 0.00% |
Real-time BOERSE MUENCHEN, June 20, 2024 at 08:43 am
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,023
JPY
Average target price
4,744
JPY
Spread / Average Target
+17.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.93% | 803B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.49% | 243B | |
| +1.88% | 228B | |
| +10.11% | 217B | |
| +6.24% | 164B | |
| -4.79% | 155B |
- Stock Market
- Equities
- 4502 Stock
- TKDA Stock
